# The Role of Serotonin-2C Receptors in the Rat Circadian System

Tamara Jayne Varcoe

Research Centre for Reproductive Health Discipline of Obstetrics and Gynaecology University of Adelaide, Adelaide, Australia

A thesis submitted to the University of Adelaide in fulfilment of the requirements for admission to the degree of Doctor of Philosophy

November 2007

# **TABLE OF CONTENTS**

Abstract	.vii
Declaration	ix
Acknowledgements	x
Publications arising from these studies	xi
Table of figures	. xiii
Abbreviations	. xvi

# CHAPTER 1. LITERATURE REVIEW ......1

1.1 IN	TRODUCTION	2
1.1.1	Circadian Rhythms	2
1.1.2	The Mammalian Circadian System	2
1.1.3	Light	3
1.1.4	Input Pathways Transmitting Light Information	3
1.1.5	Suprachiasmatic Nucleus	4
1.1.6	SCN Cell Autonomy	5
1.1.7	Relevance to Human Health	5
1.2 м	OLECULAR CLOCKWORK WITHIN SCN CELLS	6
1.2.1	Positive Control	7
1.2.2	Negative Control	7
1.2.3	Associated Clock and Clock Controlled Genes	8
1.2.4	Output Mechanisms	.10
1.3 PI	HASE SHIFTS	10
1.3.1	Per Genes and Phase Shifts	.11

1.3.2 Signal Transduction Pathw	2/2/2/2/2/2/2/2/2/2/2/2/2/2/2/2/2/2/2/
1.4 SEROTONIN	
1.4.1 Organisation of Serotoner	gic Input to the SCN16
1.4.2 Serotonin Receptor Expres	sion in the SCN17
1.4.3 Functional Significance of	Serotonin Receptor Expression20
1.4.4 Serotonin and the Modulat	ion of Light Input20
1.4.5 Serotonin and the Non-pho	tic Control of Circadian Rhythms22
1.4.6 Serotonin and the Transmi	ssion of Photic Information at Night24
1.4.7 Animal Models	
1.4.8 5-HT <sub>2C</sub> Receptor Structure	
1.4.9 5- $HT_{2C}$ Receptor Distribut	ion and Function29
1.5 SUMMARY	
1.6 HYPOTHESES AND AIMS	
CHAPTER 2. MATERIA	LS AND METHODS32
CHAPTER 2. MATERIA	LS AND METHODS
CHAPTER 2. MATERIA         2.1 ANIMALS AND ETHICS         2.2 IN VIVO SAMPLE COLLECTION	LS AND METHODS
<ul> <li>CHAPTER 2. MATERIA</li> <li>2.1 ANIMALS AND ETHICS</li> <li>2.2 <i>IN VIVO</i> SAMPLE COLLECTIC</li> <li>2.3 <i>IN VITRO</i> SAMPLE COLLECTIC</li> </ul>	LS AND METHODS
<ul> <li>CHAPTER 2. MATERIA</li> <li>2.1 ANIMALS AND ETHICS</li> <li>2.2 <i>IN VIVO</i> SAMPLE COLLECTIC</li> <li>2.3 <i>IN VITRO</i> SAMPLE COLLECTIC</li> <li>2.4 RNA EXTRACTION, REVERSION</li> </ul>	LS AND METHODS
<ul> <li>CHAPTER 2. MATERIAN</li> <li>2.1 ANIMALS AND ETHICS</li> <li>2.2 <i>IN VIVO</i> SAMPLE COLLECTIC</li> <li>2.3 <i>IN VITRO</i> SAMPLE COLLECTIC</li> <li>2.4 RNA EXTRACTION, REVERSING 2.4.1 Extraction of RNA using T</li> </ul>	LS AND METHODS
<ul> <li>CHAPTER 2. MATERIAN</li> <li>2.1 ANIMALS AND ETHICS</li> <li>2.2 <i>IN VIVO</i> SAMPLE COLLECTION</li> <li>2.3 <i>IN VITRO</i> SAMPLE COLLECTION</li> <li>2.4 RNA EXTRACTION, REVERSION</li> <li>2.4.1 Extraction of RNA using Table 2.4.2 RNA Extraction Using Amaging Table 2.4.2 RNA Extraction Using Table 2.4.2 R</li></ul>	LS AND METHODS
<ul> <li>CHAPTER 2. MATERIAN</li> <li>2.1 ANIMALS AND ETHICS</li> <li>2.2 <i>IN VIVO</i> SAMPLE COLLECTIC</li> <li>2.3 <i>IN VITRO</i> SAMPLE COLLECTIC</li> <li>2.4 RNA EXTRACTION, REVERSING</li> <li>2.4.1 Extraction of RNA using T</li> <li>2.4.2 RNA Extraction Using Among</li> <li>2.4.3 DNAse Treatment and Rev</li> </ul>	LS AND METHODS       32
<ul> <li>CHAPTER 2. MATERIAN</li> <li>2.1 ANIMALS AND ETHICS</li> <li>2.2 <i>IN VIVO</i> SAMPLE COLLECTION</li> <li>2.3 <i>IN VITRO</i> SAMPLE COLLECTION</li> <li>2.4 RNA EXTRACTION, REVERSING</li> <li>2.4.1 Extraction of RNA using T</li> <li>2.4.2 RNA Extraction Using Amount</li> <li>2.4.3 DNAse Treatment and Rev</li> <li>2.4.4 Primer Design</li> </ul>	LS AND METHODS
<ul> <li>CHAPTER 2. MATERIAN</li> <li>2.1 ANIMALS AND ETHICS</li> <li>2.2 <i>IN VIVO</i> SAMPLE COLLECTION</li> <li>2.3 <i>IN VITRO</i> SAMPLE COLLECTION</li> <li>2.4 RNA EXTRACTION, REVERSING</li> <li>2.4.1 Extraction of RNA using T</li> <li>2.4.2 RNA Extraction Using Amil</li> <li>2.4.3 DNAse Treatment and Rev</li> <li>2.4.4 Primer Design</li> <li>2.4.5 Polymerase Chain Reaction</li> </ul>	LS AND METHODS       32         33       33         34       33         35       36         36       37         37       35         38       37         38       38         38       38         39       38         31       38         32       38         33       38         34       36         35       38         36       37         37       38         38       38         34       35
<ul> <li>CHAPTER 2. MATERIAN</li> <li>2.1 ANIMALS AND ETHICS</li> <li>2.2 <i>IN VIVO</i> SAMPLE COLLECTION</li> <li>2.3 <i>IN VITRO</i> SAMPLE COLLECTION</li> <li>2.4 RNA EXTRACTION, REVERSING</li> <li>2.4.1 Extraction of RNA using T</li> <li>2.4.2 RNA Extraction Using Ame</li> <li>2.4.3 DNAse Treatment and Rev</li> <li>2.4.4 Primer Design</li> <li>2.4.5 Polymerase Chain Reaction</li> <li>2.4.6 Quantitation of Data</li> </ul>	LS AND METHODS       32         33       33         ON AND PREPARATION       33         ON AND PREPARATION       35         E TRANSCRIPTION AND PCR       35         riReagent       35         bion RNAqueous Kits       37         erse Transcription       37         38       38         n (PCR)       41
<ul> <li>CHAPTER 2. MATERIAN</li> <li>2.1 ANIMALS AND ETHICS</li> <li>2.2 <i>IN VIVO</i> SAMPLE COLLECTIC</li> <li>2.3 <i>IN VITRO</i> SAMPLE COLLECTIC</li> <li>2.4 RNA EXTRACTION, REVERSING</li> <li>2.4.1 Extraction of RNA using T</li> <li>2.4.2 RNA Extraction Using Amounts</li> <li>2.4.3 DNAse Treatment and Rev</li> <li>2.4.4 Primer Design</li> <li>2.4.5 Polymerase Chain Reaction</li> <li>2.4.6 Quantitation of Data</li> <li>2.4.7 βactin as a Housekeeper</li> </ul>	LS AND METHODS       32         33       33         on And PREPARATION       33         ON AND PREPARATION       35         E TRANSCRIPTION AND PCR       35         riReagent       35         bion RNAqueous Kits       37         erse Transcription       37         38       38         n (PCR)       41         41       41

2.4.8 Sequencing Primers	46
2.5 RADIOIMMUNOASSAY TO ANALYSE PLASMA MELATONIN CONCE	NTRATION48
2.6 URINARY MELATONIN METABOLITE COLLECTION AND PROCESSIN	NG 49
2.7 CORE BODY TEMPERATURE MONITORING	50
2.8 SCN2.2 CELL CULTURE	51
2.8.1 Cell Culture	51
2.8.2 Immunohistochemistry	51
2.9 DATA ANALYSIS	53
CHAPTER 3. ACUTE EFFECTS OF 5-HT <sub>2C</sub> RECEPT	OR
ACTIVATION IN VIVO	54
3.1 INTRODUCTION	55
3.2 METHODS AND RESULTS	57
3.2.1 Clock Gene Rhythmicity in 12L:12D Conditions	57
3.2.2 The acute effects of light exposure or DOI administration on clock g	ene
expression in the SCN	60
3.2.3 The effects of RO-60 0175 on clock gene expression at ZT16 and ZT	2264
3.2.4 The effects of DOI or RO-60 0175 on clock gene expression at CT10	966
3.3 DISCUSSION	67
CHAPTER 4. CHRONIC EFFECTS OF 5-HT <sub>2C</sub> RECE	PTOR
ACTIVATION IN VIVO	73
4.1 INTRODUCTION	74
4.2 METHODS AND RESULTS	76

4.2.1	Phase shifting effects of 5-HT <sub>2C</sub> receptor activation on clock gene expression
	in the SCN 24 hours after treatment76
4.2.2	Phase shifting effects of 5-HT <sub>2C</sub> receptor activation on clock gene expression
	in the SCN and in peripheral tissue 3 days after treatment79
4.2.3	Phase shifting effects of 5-HT <sub>2C</sub> receptor activation on rhythms of core body
	temperature
4.2.4	Specificity of activation: the effects of specific 5- $HT_{2C}$ receptor agonists and
	antagonists on aMT.6S rhythms
4.3 DIS	scussion
СНАРТ	TER 5 ACUTE FFFFCTS OF 5-HT <sub>20</sub> RECEPTOR
	ERS. ACOTE EFFECTS OF 5-111 <sub>20</sub> RECEITOR
ACTIV	ATION <i>IN VITRO</i> 94
5.1 IN	TRODUCTION
5.2 ME	ETHODS AND RESULTS
5.2.1	Serotonin receptor expression in culture
5.2.2	Temporal expression of clock and clock controlled genes in culture
5.2.3	Dose response relationship between glutamate and c-fos expression in vitro101
5.2.4	Phase dependent effects of glutamate administration in vitro
5.2.5	The effect of 5-HT <sub>2C</sub> receptor activation on c-fos and Per1 expression in the
	cultured SCN
5.2.6	The effect of glutamate and DOI on c-fos and Per1 expression at various
	circadian times107
5.3 DI	SCUSSION
CHAPI	EK 0. ANALYSIS OF 5-HT KECEPTOK EXPRESSION
IN THE	SCN2.2 CELL LINE118

CHAPTER 8. REFERENCES	143
CHAPTER 7. CONCLUSIONS AND SUMMARY	134
6.3 DISCUSSION	
6.2.4 Analysis of NeuN immunoreactivity	129
expression	125
6.2.3 The acute effect of 5-HT <sub>1B</sub> and 5-HT <sub>2A</sub> receptor activation on c-fos and	d Perl
6.2.2 Analysis of 5- $HT_{1B}$ receptor immunoreactivity	123
6.2.1 Analysis of Serotonin Receptor Expression Using PCR	121
6.2 METHODS AND RESULTS	121
6.1 INTRODUCTION	119

#### ABSTRACT

The suprachiasmatic nucleus receives dense serotonergic projections from the raphe nuclei and this input has been implicated in the modulation of circadian rhythms. This input appears to have many functions including the transmission of non-photic information during the day and the modulation of photic information at night. However, it has emerged that this input may also be involved in the transmission of light information with activation of  $5-HT_{2C}$  receptors at night having a photo-mimetic effect. The studies described in this thesis aim to clarify the role of  $5-HT_{2C}$  receptors in the control of circadian rhythms in the rat model and compare their actions to light.

The acute effects of  $5\text{-HT}_{2C}$  receptor agonist administration on clock gene expression were investigated in the rat SCN. Systemic administration of the  $5\text{-HT}_{2A/2C}$  agonist DOI to rats during early night induced *c-fos*, *Per1* and *Per2* expression in a manner similar to light. This response was time of day dependent with maximal induction occurring in the early night, and no response during the day. The role of  $5\text{-HT}_{2C}$  receptors in this response was confirmed with the use of the selective  $5\text{-HT}_{2C}$  receptor agonist RO-60 0175.

The effect of  $5\text{-HT}_{2C}$  receptor activation on the phase of expression of various circadian rhythms including temperature, melatonin and clock gene expression in the SCN and periphery was examined. Both DOI administration and light exposure at night phase delayed rhythms of melatonin and temperature. Similarly, the selective  $5\text{-HT}_{2C}$  receptor agonist RO-60 0175 phase delayed rhythms of 6-sulphatoxymelatonin, a response which was antagonised by the  $5\text{-HT}_{2C}$  receptor antagonist SB-242084. The expression of functional and clock genes within the pineal was also phase delayed following both light and  $5\text{-HT}_{2C}$  receptor agonist administration. However, the phase of expression of clock genes within the

SCN or liver did not shift in response to either a single nocturnal light pulse or agonist administration.

To investigate the site of action of  $5\text{-HT}_{2C}$  receptor agonists, rat SCN explants were maintained in culture allowing exposure of agonists to denervated tissue. The acute effect of DOI administration at various circadian times on *c-fos* and *Per1* expression was assessed. 5-HT<sub>2C</sub> receptor activation significantly increased *Per1* expression when administered during early subjective night, but had no effect during either subjective day or late subjective night, similar to that observed *in vivo*.

Finally, the suitability of immortalised rat SCN cells for investigation of the intracellular actions of  $5\text{-}HT_{2C}$  receptors in the circadian system was assessed. Using RT-PCR the expression of various serotonin receptors in the SCN2.2 cell line was compared with that observed in punches of adult rat SCN. The mRNA for  $5\text{-}HT_{1B}$  and  $5\text{-}HT_{2A}$  receptor was expressed in both the SCN2.2 cell line and the adult rat SCN. However,  $5\text{-}HT_{2C}$  receptor mRNA along with  $5\text{-}HT_3$  receptor,  $5\text{-}HT_{5A}$  receptor and  $5\text{-}HT_7$  receptor mRNA was expressed in the adult rat SCN tissue but not the SCN2.2 cells. These significant differences in serotonin receptor expression limit the usefulness of this cell line for further investigation.

Together these experiments further implicate  $5\text{-HT}_{2C}$  receptors in the control of circadian rhythms. The role of these receptors appears limited to early night, with activation showing photo-mimetic responses. Furthermore, the location of action appears to be post-synaptic within the SCN, altering the core clock genes, which in turn phase delay various circadian rhythms.

### DECLARATION

This work contains no material which has been accepted for the award for any other degree or diploma in any university or any other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I further grant my consent to the University of Adelaide to make this thesis available for loan and photocopying once accepted for the degree.

The author acknowledges that copyright of published works contained within this thesis (as listed on page xi) resides with the copyright holder/s of those works.

Tamara Jayne Varcoe November 2007

#### **ACKNOWLEDGEMENTS**

I would like to thank my supervisor Associate Professor Dave Kennaway for not only providing me with the opportunity to undertake research within his laboratory, but actively encouraging me to do so. I have learnt many skills which will be invaluable throughout my career including persistent optimism, even in the face of seemingly overwhelming odds.

I would also like to thank the members of the Circadian Physiology Research Group who were always willing to provide advice and assistance, including late night trips to the animal house. In particular, Robert Moyer for providing expert advice about immunohistochemsitry, Athena Voultsios for her advice on the peculiarities of PCR, Mark Salkeld for assisting with SCN microdissections, and Annie Connelly for her help with the 6-sulphatoxymelatonin experiments. Thankyou also to staff and students of the Discipline of Obstetrics and Gynaecology, in particular Helen Irving-Rodgers with advice regarding fluorescence immunohistochemistry and Lyn Harland for her molecular biology expertise.

These studies were conducted with the financial assistance of the National Health and Medical Research Council through a grant to D.J. Kennaway. I would also like to thank the Australian Government for providing financial support through an Australian Postgraduate Award.

Finally, I would like to thank Jim for his continual support throughout this long and sometimes arduous process, for making me call from work when I arrived late at night, and for looking after our son when I couldn't.

# PUBLICATIONS AND ABSTRACTS ARISING FROM THESE STUDIES

Publications:

Varcoe, T.J., Kennaway, D.J. and Voultsios, A. Activation of  $5\text{-HT}_{2C}$  receptors acutely induces *Per* gene expression in the rat suprachiasmatic nucleus at night. Molecular Brain Research 119: 192-200, 2003.

Varcoe, T.J. and Kennaway, D.J. (in preparation)

Activation of 5-HT<sub>2C</sub> receptors acutely induces *Per* gene expression in the rat suprachiasmatic nucleus in vitro.

Abstracts:

<u>Varcoe, T.J.</u> and Kennaway, D.J. "5- $HT_{2C}$  receptors and the transmission of photic information at night: site of action". Australasian Chronobiology Society International Conference, From Molecular Clocks to Human Health, Adelaide, Australia, 2007

<u>Varcoe, T.J.</u> and Kennaway, D.J. "The role of 5-HT<sub>2C</sub> receptors in the rat circadian system". 1<sup>st</sup> Annual Meeting of the Australasian Chronobiology Society, Robe, South Australia, Australia, 2004.

<u>Varcoe, T.J.</u>, Kennaway, D.J. and Voultsios, A. "The effects of 5-HT<sub>2C</sub> receptor agonists on clock gene expression in the rat suprachiasmatic nucleus". Japan 1<sup>st</sup> World Congress of Chronobiology, Sapporo, Japan, 2003

<u>Varcoe, T.J.</u>, Kennaway, D.J. and Voultsios, A. "Manipulating circadian rhythms with a serotonin agonist". Australian Society for Medical Research. National Scientific Meeting, Adelaide, Australia, 2003.

<u>Varcoe, T.J.</u>, Kennaway, D.J. and Voultsios, A. "Serotonin receptors and circadian rhythms". Australian Society for Medical Research. South Australian Annual Scientific Meeting, Adelaide, Australia, 2003

### **TABLE OF FIGURES**

Figure 1-1	The Mammalian Circadian System	2
Figure 1-2	Molecular machinery generating circadian rhythms	8
Figure 1-3	Signal Transduction Pathways utilised following NMDA/AMPA receptor activation leading to CREB phosphorylation and <i>Per1</i> induction	14
Figure 1-4	Serotonergic input to the SCN	17
Figure 2-1	Demonstration of the SCN tissue collection procedure	34
Figure 2-2	Histology section of rat brain after removal of one SCN	34
Figure 2-3	Amplification efficiency of the housekeeper gene β <i>actin</i> and the clock genes <i>Per1</i> , <i>Per2</i> , <i>Per3</i> , <i>Cry1</i> , <i>Cry2</i> , <i>Clock</i> and <i>Bmal1</i>	43
Figure 2-4	Amplificiation efficiency of the clock controlled genes <i>c-fos</i> , <i>Dec1</i> , <i>Dec2</i> , <i>Rev-erba</i> , <i>DBP</i> and <i>PK2</i> , the neuropeptide <i>VIP</i> and the melatonin recentor $MTl$	ЛЛ
Figure 2-5	Amplification efficiency of the serotonin receptors 5-HT <sub>1A</sub> , 5-HT <sub>1B</sub> , 5-HT <sub>2A</sub> , 5-HT <sub>2C</sub> , 5-HT <sub>3</sub> , 5-HT <sub>5A</sub> and 5-HT <sub>7</sub> .	45
Figure 2-6	Agarose gel of PCR products	47
Figure 3-1	The temporal expression of clock ( <i>Per1, Per2, Per3, Clock, Bmal1, Cry1, Cry2, Dec1</i> and <i>Dec2</i> ), clock controlled ( <i>Rev-erba, DBP</i> and <i>Prokineticin2</i> ), and other genes of interest ( <i>c-fos</i> and <i>5-HT<sub>2C</sub> receptor</i> ) in the rat SCN across 24 hours.	59
Figure 3-2	The effect of light (400 lux, 15minutes) or DOI (2mg/kg) on <i>c-fos</i> , <i>Per1</i> and <i>Per2</i> expression in the rat SCN at ZT16 or ZT22	62
Figure 3-3	The effect of light (400 lux, 15 minutes) at ZT16 and ZT22 on <i>Bmal1</i> , <i>Cry1</i> and <i>Clock</i> gene expression in the rat SCN	63
Figure 3-4	The effect of RO 60-0175 administration (10 mg/kg) on rat SCN <i>c-fos</i> , <i>Per1</i> , <i>Per2</i> , <i>Dec1</i> and <i>Dec2</i> expression 30 minutes after administration at ZT16 and ZT22.	65

Figure 3-5	The effect of DOI (2 mg/kg) or RO-60 0175 (10 mg/kg) administration	
	on <i>c-fos</i> , <i>Per1</i> and <i>Per2</i> expression in the rat SCN at CT10	66
Figure 4-1	The effects of DOI (2 mg/kg) or light (400 lux, 15 min) at CT16 on plasma melatonin levels on the night following treatment	77
Figure 4-2	The effect of DOI (2 mg/kg) or light (400 lux, 15 min) at CT16 on <i>Per1</i> expression in the SCN across the day and night following treatment	78
Figure 4-3	The effect of DOI (2 mg/kg) or light (400 lux, 15 min) at CT16 on <i>Per2</i> expression in the SCN across the day and night following treatment	78
Figure 4-4	The effect of DOI (2 mg/kg) or light exposure (400 lux, 15 minutes) at CT16 on plasma melatonin concentration 3 subjective nights after treatment.	80
Figure 4-5	The effect of DOI (2 mg/kg) or light exposure (400 lux, 15 minutes) at CT16 on <i>Per1</i> expression in the SCN 3 subjective nights after treatment	81
Figure 4-6	The effect of DOI (2 mg/kg) or light exposure (400 lux, 15 minutes) at CT16 on AA- <i>N</i> -Acetyl Transferase expression in the SCN 3 subjective nights after treatment.	82
Figure 4-7	The effect of DOI (2 mg/kg) or light exposure (400 lux, 15 minutes) at CT16 on <i>Per1</i> expression in the pineal 3 subjective nights after treatment.	83
Figure 4-8	The effect of DOI (2 mg/kg) or light exposure (400 lux, 15 minutes) at CT16 on <i>Perl</i> expression in the liver 3 subjective nights after treatment	84
Figure 4-9	The effect of DOI (2 mg/kg), light (2 lux, 15 min) and saline on core body temperature offset	86
Figure 4-10	0 The effect of RO-60 0175 (5 and 10 mg/kg) and SB-242084 (10 mg/kg) on the phase of aMT.6S excretion rhythms in the rat	88
Figure 5-1	<i>5-HT<sub>2C</sub> receptor</i> mRNA expression in SCN from 21 day old rats maintained in culture for up to 3 days	98
Figure 5-2	Clock, MT1 receptor, 5-HT <sub>1B</sub> receptor, 5-HT <sub>2C</sub> receptor, 5-HT <sub>5A</sub> receptor, VIP and NMDA receptor1 mRNA expression in rat SCN in culture	98

Figure 5-3	The temporal expression of <i>Per1</i> , <i>Per2</i> , <i>Bmal1</i> , <i>Prokineticin2</i> , 5-HT <sub>2C</sub>	
	receptor and Rev-erb $\alpha$ mRNA in the isolated rat SCN after 48 hours of	
	culture	100
Figure 5-4	The effect of increasing doses of glutamate on <i>c-fos</i> expression 60	
	minutes after the initiation of treatment at CT16	102
Figure 5-5	Phase response curve of <i>c-fos</i> mRNA following application of glutamate	
	(10 mM) to rat SCN <i>in vitro</i>	104
Figure 5-6	The effect of increasing dose of DOI on <i>c-fos</i> and <i>Per1</i> mRNA 60 or 120	
	minutes after the initiation of treatment at CT16	106
Figure 5-7	The effect of glutamate (10 mM) and DOI (1 mM) on <i>c-fos</i> and <i>Per1</i>	100
	expression in the cultured fat SCN	109
Figure 5-8	Comparative effects of DOI on <i>c-fos</i> and <i>Per1</i> expression in the rat SCN either <i>in vivo</i> or <i>in vitro</i>	
Figure 6 1	Amplification curves showing the expression of the selected serotonin	
riguie 0-1	receptors, <i>Per1</i> and <i>MT1 receptor</i> in representative rat SCN and SCN2.2	
	cells	122
Figure 6-2	5-HT <sub>1B</sub> receptor immunoreactivity in the SCN2.2 cell line	124
Figure 6-3	The effect of a 2 hour serum shock on <i>Per2</i> and <i>Bmal1</i> expression in	
	SCN2.2 cells	126
Figure 6-4	The effect of CGS 12060 (1 $\mu$ M, 15 minutes) or DOI (1 $\mu$ M, 15 minutes)	
	on <i>c-fos</i> and <i>Per1</i> expression in the SCN2.2 cell line 36 hours following	100
	a serum shock	128
Figure 6-5	NeuN staining in both the SCN2.2 cell line and adult rat brain	130
Figure 7-1	A model of the role of serotonin in phase delays	141
Figure 7-2	A model of the role of serotonin in phase advances.	142

## ABBREVIATIONS

5,7-DHT	5,7-dihydroxytryptamine
5-HT	5-hydroxytryptamine (serotonin)
AA-NAT	Arylalkylamine N-acetyltransferase
AMPA	alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
ANOVA	Analysis of variance
ARNT	aryl hydrocarbon receptor nuclear translocator
AVP	Arginine vasopressin
aMT.6S	6-sulphatoxymelatonin
bHLH	basic helix loop helix
BLAST	Basic local alignment search tool
BMAL1	Brain muscle ARNT like protein 1
CaM	Calcium calmodulin
cAMP	cyclic adenosine monophosphate
CBP	CREB binding protein
cDNA	complementary deoxyribonucleic acid
cGMP	cyclic guanosine monophosphate
CK1ɛ	Casein kinase 1 epsilon
CLOCK	Circadian locomotor output cycles kaput
CNS	Central nervous system
CRE	cAMP response element
CREB	cAMP response element binding protein
CRY	Cryptochrome
СТ	Circadian time
Ct	Cycle threshold
DAG	Diaminoglycerol

DAPI	4',6-diamidino-2-phenylindole
DBP	Albumin D-site binding protein
df	degrees of freedom
DMH	Dorsomedial hypothalamus
DNA	Deoxyribonucleic acid
dNTP	Deoxyribonucleotide triphosphate
DOB	(-)-1-2, 5-dimethoxy-4-bromophenyl-2-aminopropane
DOI	1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine
DTT	Dithiothreitol
EPSC	Excitatory post synaptic current
FBS	Fetal bovine serum
GABA	Gamma-aminobutyric acid
GHT	Geniculohypothalmic tract
IGL	Intergeniculate leaflet
IP <sub>3</sub>	Inositol tri-phosphate
MAP2	Microtubule associated protein 2
MAPK	Mitogen activated protein kinase
mCPBG	m-Chlorophenylbiguanidine
mRNA	messenger ribonucleic acid
MT1	Melatonin receptor 1
NAT	N-acetyltransferase
NeuN	Neuronal Nuclei
NMDA	N-methyl-D-aspartic acid
NOS	Nitrous oxide synthase
NPY	Neuropeptide Y
NSB	Non-specific binding
NSE	Neuron specific enolase

OC	Optic chiasm
PACAP	Pituitary adenylate cyclase-activating peptide
PAS	Per-ARNT-Sim
PBS	Phosphate buffered saline
PCR	Polymerase chain reaction
pCREB	phosphorylated cAMP response element binding protein
pCPA	p-Chlorophenylalanine
PDE	Phosphodiesterase
PER	Period
PGP	Protein gene product 9.5
PK2	Prokineticin2
РКС	Protein kinase C
PKG	Protein kinase G
PLC	Phospholipase C
PRC	Phase response curve
PVN	Paraventricular nucleus
RHT	Retinohypothalamic tract
RNA	Ribonucleic acid
RORa	retinoic acid-receptor-related orphan receptor alpha
RORE	retinoic acid-receptor-related orphan receptor response element
RT-PCR	Reverse transcription polymerase chain reaction
RyR	Ryanodine receptor
SAD	Seasonal affective disorder
s/c	subcutaneous
SCN	Suprachiasmatic nucleus
TBE	Tris-borate-EDTA
TGFα	Transforming growth factor alpha

TTX	Tetrodotoxin
VIP	Vasoactive intestinal peptide
ZT	zeitgeber time